Abstract
This study aimed to evaluate the effect of a strong CYP3A inducer, rifampin, on glasdegib pharmacokinetics in healthy volunteers. In an open-label, fixed-sequence, two-period Phase 1 study, subjects received a single 100-mg oral dose of glasdegib alone or following once-daily pre-treatment with 600 mg rifampin. Glasdegib pharmacokinetics were calculated using a noncompartmental analysis. Twelve healthy male volunteers (3 whites, 5 blacks and 4 others) were enrolled in the study. Mean age, weight, height and body mass index was 37.8 years, 83.0 kg, 177.3 cm and 26.5 kg (m2 ) -1 , respectively. When dosed alone, glasdegib geometric mean (% coefficient of variation) area under the plasma concentration-time curve from time zero to infinity (AUCinf ) was 8145 ng × h ml-1 (23%) and maximum observed concentration (Cmax ) was 703.2 ng ml-1 (19%). With rifampin, glasdegib AUCinf and Cmax decreased, with an adjusted geometric mean ratio (90% confidence interval) 29.66% (26.17-33.62) for AUCinf and 64.71% (57.21-73.19) for Cmax . Mean terminal half-life decreased from 13.39 to 5.11 hours, geometric mean apparent oral clearance increased from 12.27 to 41.38 l h-1 , whereas median time to Cmax remained similar (1.50 vs. 1.25 hours) in the p...Continue Reading
References
Oct 1, 1975·Clinical Pharmacology and Therapeutics·G R Wilkinson, D G Shand
Sep 17, 2008·Genes & Development·Markku Varjosalo, Jussi Taipale
Feb 9, 2012·ACS Medicinal Chemistry Letters·Michael J MunchhofGeorge T Tkalcevic
Jun 20, 2014·Cancer Chemotherapy and Pharmacology·M Naveed ShaikWendy J Levin
Nov 13, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andrew J WagnerAnthony B El-Khoueiry
Dec 22, 2015·The Lancet. Haematology·Giovanni MartinelliCatriona Jamieson
Feb 4, 2016·Development·Raymond Teck Ho LeePhilip W Ingham
Feb 20, 2016·Cancers·Tadas K RimkusHui-Wen Lo
Aug 4, 2016·Oncotarget·Giorgia GiordaniRoberto Bernardoni
Nov 22, 2016·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Justine L LamM Naveed Shaik
May 31, 2017·Cancer Science·Yosuke MinamiTomoki Naoe
Oct 22, 2017·British Journal of Pharmacology·Stephen Ph AlexanderUNKNOWN CGTP Collaborators
Oct 22, 2017·British Journal of Pharmacology·Stephen Ph AlexanderUNKNOWN CGTP Collaborators
Nov 1, 2017·Cancer Chemotherapy and Pharmacology·Nagdeep GiriM Naveed Shaik
Nov 18, 2017·Nucleic Acids Research·Simon D HardingUNKNOWN NC-IUPHAR
Citations
Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Richard L Carpenter, Haimanti Ray
Apr 13, 2019·Clinical Pharmacology in Drug Development·Naveed ShaikRobert Roland LaBadie
Aug 23, 2019·Future Oncology·Anna Wolska-Washer, Tadeusz Robak
Feb 7, 2020·Expert Opinion on Pharmacotherapy·Xavier Thomas, Maël Heiblig
Sep 25, 2020·Leukemia & Lymphoma·Jorge E CortesMichael Heuser
Nov 27, 2019·Journal of Clinical Pharmacology·Swan LinAna Ruiz-Garcia
Jul 20, 2020·Annals of Hematology·Juan Eduardo Megías-VericatPau Montesinos
Dec 12, 2018·Cancer Chemotherapy and Pharmacology·Naveed ShaikRobert R LaBadie
Nov 21, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Valerie ReliasIlene Galinsky
Dec 29, 2020·Clinical Pharmacology in Drug Development·Joanna C MastersNaveed Shaik
May 18, 2021·Expert Review of Clinical Pharmacology·Luke K FostvedtAna Ruiz-Garcia